Pfizer announced positive top-line results from the company’s year-long Phase III trial of etrasimod for the treatment of ulcerative colitis (UC). Pfizer plans to pursue regulatory filings for the drug during 2022.

Celgene Corporation announced that the company submitted a New Drug Application to the U.S. FDA for ozanimod for the treatment of adults with relapsing forms of multiple sclerosis (RMS).

Biogen, Inc., headquartered in Cambridge, Mass., announced today that it licensed MT-1303 from Mitsubishi Tanabe Pharma Corporation, located in Osaka, Japan. MT-1303 is being investigated in a number of autoimmune […]